FDA Drug Approval Calendar

MarketBeat's FDA Calendar tracks confirmed drug approvals, clinical trial results, regulatory decisions, and biotech catalysts — updated daily with real-time stock data. Review recent FDA actions including New Drug Application (NDA) approvals, Biologics License Application (BLA) decisions, Complete Response Letters (CRLs), Phase 1–3 trial results, and special designations like Breakthrough Therapy or Orphan Drug status.

Each entry includes the company ticker, current stock price, and 30-day price trend so you can quickly see how the market is responding to FDA news.

MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
0 Results
Main Company Current Price 30-Day Price Change Drug Status Event
Innate Pharma S.A. Sponsored ADR stock logo
IPHA
Innate Pharma
$1.03
-22.9%
-29.8%
The price history of IPHA in the last 30 days
IPH4502 Topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
Phase 1
11/18/2026 - Initial Data Innate Pharma SA announced initial Phase 1 data from its ongoing study of IPH4502, an investigationa…
Full Summary
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$2.94
+8.0%
-18.6%
The price history of RXRX in the last 30 days
REC-4881 Familial Adenomatous Polyposis (FAP)
Phase 3
11/18/2026 - Provided Update Recursion announced that it has aligned with the FDA on the design of its registrational Phase 3 tri…
Full Summary
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$10.65
-0.2%
-31.6%
The price history of SMMT in the last 30 days
Ivonescimab For Lung cancer
Phase 3
11/18/2026 - Initiation Summit Therapeutics Inc. announced the initiation of a new global Phase III clinical trial of ivone…
Full Summary
Novabridge Biosciences stock logo
NBP
Novabridge Biosciences
$0.88
+6.5%
-32.6%
The price history of NBP in the last 30 days
VIS-101 in patients with wet age-related macular degeneration (wet AMD).
Phase 2b
11/18/2026 - Dose Update Visara, Inc subsidiary of NovaBridge Biosciences, Inc. announced that the first patient has been d…
Full Summary
OPTH
Optimi Health
$1.99
-5.2%
-40.2%
The price history of OPTH in the last 30 days
OPTI-201 in Major Depressive Disorder 11/18/2026 - Provided Update Optimi Health Corp provides an update on its clinical programs, commercial supply, Ibogaine Initiati…
Full Summary
Immuneering Corporation stock logo
IMRX
Immuneering
$3.56
+2.7%
-2.9%
The price history of IMRX in the last 30 days
Atebimetinib in Pancreatic Cancer 11/18/2026 - Findings Update Immuneering Corporation announced compelling preclinical data that supports expanding the clinical d…
Full Summary
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
$27.59
+2.3%
-37.8%
The price history of IONS in the last 30 days
Olezarsen (Formerly IONIS-APOCIII-L) Severe hypertriglyceridemia EC Approval 11/17/2026 - Approved Ionis Pharmaceuticals, Inc. announced that the European Commission (EC) has approved TRYNGOLZA™ (ol…
Full Summary
EIKN
Eikon Therapeutics
$5.31
+3.1%
-31.0%
The price history of EIKN in the last 30 days
EIK1006 in Advanced Metastatic Prostate Cancer
IND
11/17/2026 - FDA Clearance ikon Therapeutics, announced U.S. Food and Drug Administration clearance to proceed for the Invest…
Full Summary
EIKN
Eikon Therapeutics
$5.31
+3.1%
-31.0%
The price history of EIKN in the last 30 days
EIK1006 in Advanced Metastatic Prostate Cancer Phase 1/2
Target date: H2 2027
11/17/2026 - Initial Data Eikon Therapeutics, Inc. announced that Initial clinical data from Phase 1/2 study expected in sec…
Full Summary
Medtronic PLC stock logo
MDT
Medtronic
$101.10
-1.2%
+8.9%
The price history of MDT in the last 30 days
Hugo for gynecological procedures 11/17/2026 - FDA Clearance Medtronic plc announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-as…
Full Summary
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$951.41
-0.7%
+21.7%
The price history of REGN in the last 30 days
Libtayo (cemiplimab) Advanced Cervical Cancer EC Approval 11/17/2026 - Approved Regeneron Pharmaceuticals, Inc announced that the European Commission (EC) has approved an alternat…
Full Summary
Sanofi stock logo
SNY
Sanofi
$47.35
-0.4%
+19.7%
The price history of SNY in the last 30 days
Libtayo (cemiplimab) Advanced Cervical Cancer EC Approval 11/17/2026 - Approved Regeneron Pharmaceuticals, Inc announced that the European Commission (EC) has approved an alternat…
Full Summary
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$19.98
+4.4%
+90.5%
The price history of SLS in the last 30 days
galinpepimut-S (GPS) Targets the WT1 protein, which is present in an array of tumor types. 11/17/2026 - Top-line results SELLAS Life Sciences Group, Inc. announced positive topline results from the pivotal randomized Phas…
Full Summary
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.73
-0.2%
+55.7%
The price history of LUNG in the last 30 days
AeriSeal For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation. 11/17/2026 - Publication Pulmonx Corporation announced the online publication of results from the CONVERT Trial evaluating t…
Full Summary
Veru Inc. stock logo
VERU
Veru
$2.30
+7.5%
-0.4%
The price history of VERU in the last 30 days
Enobosarm ER+/HER2- breast cancer 11/17/2026 - Presentation Veru Inc. announced that Veru had a podium presentation at ObesityWeek 2026 in Washington DC.
Full Summary
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$18.16
-0.9%
-8.3%
The price history of ACAD in the last 30 days
Remlifanserin Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis 11/17/2026 - Additional data Acadia Pharmaceuticals Inc today presented additional data from the Phase 2 RADIANT trial evaluating…
Full Summary
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$123.96
neladalkib advanced ALK-positive solid tumors outside of non-small cell lung cancer (NSCLC). 11/17/2026 - Approved GSK plc announced the US Food and Drug Administration (FDA) has granted accelerated approval to Nelk…
Full Summary
Biogen Inc. stock logo
BIIB
Biogen
$251.98
+0.5%
+7.9%
The price history of BIIB in the last 30 days
diranersen Alzheimer’s disease 11/17/2026 - New Data Biogen Inc. announced new data from the Phase 2 CELIA study showing increasing clinical benefit of d…
Full Summary
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.18
-0.4%
-6.0%
The price history of GANX in the last 30 days
rexaceract Parkinson’s Disease and Related Disorders
Phase 1b
11/17/2026 - Late Breaking Presentation Gain Therapeutics, Inc. announced the late-breaking presentation of clinical data from the Phase 1…
Full Summary
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.46
+2.2%
-0.7%
The price history of ACRS in the last 30 days
ATI-045 In Atopic Dermatitis (AD)
Phase 2
11/16/2026 - Top-line results Aclaris Therapeutics, Inc. announced top line results from the Phase 2 ADMIRATION trial that evaluat…
Full Summary
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$3.46
+2.2%
-0.7%
The price history of ACRS in the last 30 days
ATI-2138 For the Treatment of Moderate to Severe Atopic Dermatitis
Phase 2b
11/16/2026 - Initiation Aclaris Therapeutics, Inc. announced initiation of its randomized, double-blind, placebo-controlled…
Full Summary
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$51.55
-0.2%
-17.7%
The price history of CYTK in the last 30 days
Aficamten Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) supplemental New Drug Application (sNDA) 11/16/2026 - FDA approved Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved …
Full Summary
Cybin Inc. stock logo
HELP
Cybin
$6.81
-5.5%
-36.3%
The price history of HELP in the last 30 days
HLP003 adjunctive treatment of major depressive disorder ("MDD")
Phase 3
11/16/2026 - Top-line results Helus Pharma Inc. announced positive topline results from APPROACH, its Phase 3 pivotal study evalua…
Full Summary
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$0.85
+0.9%
-3.6%
The price history of CRDF in the last 30 days
onvansertib in Chronic Myelomonocytic Leukemia
Fast Track
11/16/2026 - Designation Grant Cardiff Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast T…
Full Summary
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$0.37
+4.1%
-32.8%
The price history of RNTX in the last 30 days
LTI-03 In Idiopathic Pulmonary Fibrosis
Phase 2
11/16/2026 - Observations Rein Therapeutics announced preliminary blinded twelve-week observations from the ongoing RENEW Phas…
Full Summary
Radiopharm Theranostics Limited - Sponsored ADR stock logo
RADX
Radiopharm Theranostics
$0.71
+6.0%
-32.2%
The price history of RADX in the last 30 days
RAD101 patients with indeterminate brain metastases following radiotherapy.
Phase 2b
11/16/2026 - Data Radiopharm Theranostics announced that data from the Phase 2b imaging study of RAD101 in suspected …
Full Summary
BioVie Inc. stock logo
BIVI
BioVie
$0.98
-1.5%
-28.5%
The price history of BIVI in the last 30 days
Bezisterim For Parkinson's Disease Patients
Phase 2
11/16/2026 - Findings Update BioVie Inc. announced new clinical and biomarker findings from the Phase 2 ADDRESS-LC trial of bezis…
Full Summary
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$2.67
-11.3%
-40.1%
The price history of CRBP in the last 30 days
CRB-913 For Obesity 11/16/2026 - Additional data Corbus Pharmaceuticals Holdings, Inc announced today that additional data from the CANYON-1 Phase 1…
Full Summary
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.37
+11.9%
-2.3%
The price history of ESLA in the last 30 days
ARTEMIS T for cancer and autoimmune diseases 11/16/2026 - Findings Update Estrella Immunopharma, Inc. today highlighted preclinical findings from an abstract accepted for po…
Full Summary
MediWound Ltd. stock logo
MDWD
MediWound
$13.90
+1.6%
+9.4%
The price history of MDWD in the last 30 days
EscharEx Chronic Wounds 11/16/2026 - Provided Update MediWound Ltd. announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, De…
Full Summary
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$3.92
+0.4%
-12.7%
The price history of NUVB in the last 30 days
Safusidenib Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
Phase 2
11/16/2026 - Follow-up data Nuvation Bio Inc. announced new long-term follow-up data from the Phase 2 (J201) study of investiga…
Full Summary
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$101.81
+0.0%
+1.9%
The price history of LNTH in the last 30 days
TAUKLARIFY PET Imaging in Early Alzheimer’s Disease
Phase 3
11/16/2026 - Results Lantheus Holdings, Inc. announced results from two pivotal Phase 3 studies evaluating the diagnostic…
Full Summary
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$26.41
-3.6%
-21.9%
The price history of IDYA in the last 30 days
IDE849 In Solid Tumors 11/16/2026 - Provided Update IDEAYA Biosciences, Inc. announced its registrational strategy for IDE849, a potential best-in-clas…
Full Summary
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$26.41
-3.6%
-21.9%
The price history of IDYA in the last 30 days
IDE101 Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors 11/15/2026 - Provided Update IDEAYA Biosciences, Inc announced development candidate nomination of IDE101, a potential first-in-c…
Full Summary
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
$12.13
+0.4%
-3.9%
The price history of DRTS in the last 30 days
Alpha DaRT Prostate cancer 11/15/2026 - Results Alpha Tau Medical Ltd. announced updated interim results from its U.S. REGAIN (Recurrent Glioblast…
Full Summary
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.90
+0.1%
+7.4%
The price history of VKTX in the last 30 days
VK2735 Metabolic disorders 11/15/2026 - Poster Presentation Viking Therapeutics, Inc announced that new clinical data from the company's VK2735 obesity program…
Full Summary
Cybin Inc. stock logo
HELP
Cybin
$6.81
-5.5%
-36.3%
The price history of HELP in the last 30 days
HLP003 adjunctive treatment of major depressive disorder ("MDD") 11/15/2026 - Provided Update Helus Pharma Inc. announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline…
Full Summary
Rezolute, Inc. stock logo
RZLT
Rezolute
$4.07
+1.5%
+10.1%
The price history of RZLT in the last 30 days
Ersodetug For Hypoglycemia Due to Congenital Hyperinsulinism
Phase 3
11/13/2026 - Positive Results Rezolute, Inc. announced positive results from the ongoing open-label Phase 3 upLIFT study of ersode…
Full Summary
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$138.97
-3.1%
-3.2%
The price history of MRK in the last 30 days
belzutifan Treated Patients With Advanced Renal Cell Carcinoma (RCC) EMA 11/13/2026 - Positive Opinion Merck announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP…
Full Summary
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$138.97
-3.1%
-3.2%
The price history of MRK in the last 30 days
ENFLONSIA™ In Infants Born During or Entering Their First RSV Season 11/13/2026 - Positive Opinion Merck announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European…
Full Summary
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$22.41
-4.7%
-6.8%
The price history of ZLAB in the last 30 days
ZL-1503 For the Treatment of Atopic Dermatitis Phase 1/1b 11/13/2026 - Preliminary Results Zai Lab Limited announced positive preliminary, first-in-human results from the single-ascending-dos…
Full Summary
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$7.49
-0.2%
-7.2%
The price history of BCRX in the last 30 days
ORLADEYO (berotralstat) Hereditary angioedema (HAE) 11/13/2026 - Provided Update BioCryst Pharmaceuticals, Inc. announced new real-world evidence on the use of once-daily ORLADEYO…
Full Summary
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
$2.84
-0.2%
-10.6%
The price history of WVE in the last 30 days
WVE-007 For obesity. 11/13/2026 - Highlights Wave Life Sciences, today highlights WVE-007 progress at ObesityWeek®, the annual congress of The O…
Full Summary
argenex SE stock logo
ARGX
argenex
$946.12
-0.1%
+14.6%
The price history of ARGX in the last 30 days
VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis 11/13/2026 - Provided Update Zai Lab Limited announced that five of its commercial medicines in China have been included in the…
Full Summary
Altimmune, Inc. stock logo
ALT
Altimmune
$1.43
-6.9%
-36.1%
The price history of ALT in the last 30 days
pemvidutide for the treatment of obesity and MASH 11/12/2026 - Publication Altimmune, Inc. announced the publication of 48-week results from the IMPACT Phase 2b trial of pemv…
Full Summary
Immuneering Corporation stock logo
IMRX
Immuneering
$3.56
+2.7%
-2.9%
The price history of IMRX in the last 30 days
Atebimetinib in Pancreatic Cancer
Phase 2
11/12/2026 - Initiation Immuneering Corporation announced plans to initiate a Phase 2 clinical trial evaluating atebimetin…
Full Summary
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$21.40
-1.1%
+9.1%
The price history of TAK in the last 30 days
ORZEYFUL treatment of narcolepsy type 1 11/12/2026 - Provided Update Takeda announced that ORZEYFUL™ (oveporexton) CIV is now available in the U.S. by prescription for t…
Full Summary
Alpha Tau Medical Ltd. stock logo
DRTS
Alpha Tau Medical
$12.13
+0.4%
-3.9%
The price history of DRTS in the last 30 days
Alpha DaRT Prostate cancer 11/12/2026 - Provided Update Alpha Tau Medical Ltd. announced that it will host a conference call and webcast on Monday, Nov. 16…
Full Summary
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$3.29
+0.8%
+3.6%
The price history of IMMP in the last 30 days
eftilagimod alpha For cancer and autoimmune disease 11/11/2026 - Survival data Immutep Limited announced the release of an abstract reporting interim disease-free survival data a…
Full Summary
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$77.92
+1.5%
+14.7%
The price history of BBIO in the last 30 days
ATTR-CM first-line treatment of choice for individuals with ATTR-CM 11/11/2026 - Abstract BridgeBio Pharma, Inc. announced 28 abstracts on acoramidis in individuals with transthyretin amylo…
Full Summary
Guardant Health, Inc. stock logo
GH
Guardant Health
$145.97
+1.9%
-7.5%
The price history of GH in the last 30 days
Guardant360 Advanced solid tumors. 11/11/2026 - Provided Update Guardant Health, Inc. announced new applications for Guardant360® Liquid designed to help oncologis…
Full Summary
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.85
+0.9%
-6.0%
The price history of VNDA in the last 30 days
Tradipitant Tradipitant is a neurokinin-1 receptor antagonist 11/11/2026 - Provided Update Vanda Pharmaceuticals Inc. announced that "NEREUS™ – The Goat of Biscayne Bay" is arriving during M…
Full Summary
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,392.09
-1.7%
+12.0%
The price history of LLY in the last 30 days
Taltz adults with psoriasis and obesity or overweight
Phase 3
11/11/2026 - Results Eli Lilly and Company announced detailed 52-week results showing improved and durable efficacy fro…
Full Summary
Coherus Oncology, Inc. stock logo
CHRS
Coherus Oncology
$0.42
-12.0%
-56.1%
The price history of CHRS in the last 30 days
toripalimab-tpzi in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) 11/11/2026 - Provided Update Oncolytics Biotech® Inc. announced today that it has entered into a clinical supply agreement with…
Full Summary
enGene Holdings Inc. stock logo
ENGN
enGene
$1.90
+10.2%
+19.9%
The price history of ENGN in the last 30 days
detalimogene voraplasmid in BCG-Unresponsive NMIBC
Phase 2
11/11/2026 - updated results enGene Therapeutics Inc. announced updated results from the pivotal Cohort 1 of its ongoing, Phase…
Full Summary
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.41
-2.4%
-22.4%
The price history of BDTX in the last 30 days
silevertinib patients with cancer
Phase 2
11/10/2026 - Updated data Black Diamond Therapeutics, Inc today reported updated data from its Phase 2 trial of silevertinib …
Full Summary
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$1.08
+5.4%
-42.2%
The price history of FATE in the last 30 days
FT819 Advanced B-cell Leukemias and Lymphomas 11/10/2026 - Updated data Fate Therapeutics, Inc. announced that updated clinical data for FT819, together with translational …
Full Summary
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$0.49
-0.6%
-42.0%
The price history of BMEA in the last 30 days
BMF-650 GLP-1 receptor agonist 11/10/2026 - Presentation Biomea Fusion, Inc. announced that it will present Phase 1 clinical results for BMF-650, its investi…
Full Summary
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$21.81
+5.6%
-9.8%
The price history of BEAM in the last 30 days
risto-cel sickle cell disease 11/10/2026 - Top-line results - Beam Therapeutics Inc. announced positive topline results from the BEACON Phase 1/2 study evaluat…
Full Summary
City Therapeutics, Inc. stock logo
CTY
City Therapeutics
$17.41
-0.5%
-18.9%
The price history of CTY in the last 30 days
CITY-RBP4 Treatment of Stargardt Disease
Phase 1
11/10/2026 - Dose Update City Therapeutics, Inc. announced that the first participant has been dosed in the Phase 1 clinical…
Full Summary
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
$12.25
+0.4%
+7.2%
The price history of KLRA in the last 30 days
ribupatide GLP-1/GIP/glucagon receptor tri-agonist in obesity. 11/10/2026 - Presentation - Kailera Therapeutics, Inc announced that new clinical and real-world research will be presented a…
Full Summary
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$92.16
+0.2%
+12.1%
The price history of MIRM in the last 30 days
brelovitug treatment of chronic hepatitis delta virus (HDV)
Phase 3
11/10/2026 - Endpoint Met Mirum Pharmaceuticals, Inc announced that the primary endpoint was met in the Phase 3 AZURE-4 study…
Full Summary
Cingulate Inc. stock logo
CING
Cingulate
$5.12
+8.5%
+17.4%
The price history of CING in the last 30 days
CTx-1301 Attention Deficit/Hyperactivity Disorder (ADHD) 11/10/2026 - Regulatory Update Cingulate Inc. announced today that Chairman and CEO Shane J. Schaffer has provided an update on th…
Full Summary
BioVie Inc. stock logo
BIVI
BioVie
$0.98
-1.5%
-28.5%
The price history of BIVI in the last 30 days
Bezisterim For Parkinson's Disease Patients 11/10/2026 - Oral presentation BioVie Inc. announced the Company has been invited to present two oral presentations at the AD/PD202…
Full Summary
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,392.09
-1.7%
+12.0%
The price history of LLY in the last 30 days
orforglipron Orforglipron for the treatment of obesity and overweight 11/10/2026 - Provided Update Eli Lilly and Company announced the launch of Life Doesn't Slow Down, a new campaign for Lilly's Fo…
Full Summary
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$276.08
-0.9%
+8.7%
The price history of JNJ in the last 30 days
CAPLYTA (Lumateperone) Depressive Episodes associated with Bipolar
Phase 3
11/10/2026 - Pivotal Study Johnson & Johnson announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lu…
Full Summary
Lipocine Inc. stock logo
LPCN
Lipocine
$1.55
-3.1%
+1.3%
The price history of LPCN in the last 30 days
LPCN 1154 Postpartum depression (PPD)
Phase 3
11/10/2026 - Dose Update Lipocine Inc announced that the first participant has been dosed in BLOOM, the Company's Phase 3 stu…
Full Summary
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.96
-4.8%
-28.2%
The price history of PALI in the last 30 days
PALI-2108 For patients affected by UC. 11/10/2026 - Provided Update Palisade Bio, Inc. provided a business update highlighting continued execution of its Phase 2 clinic…
Full Summary
Metagenomi, Inc. stock logo
MGX
Metagenomi
$0.65
+2.2%
-20.5%
The price history of MGX in the last 30 days
MGX-001 Hemophilia A gene editing investigational therapy 11/10/2026 - FDA Clearance Metagenomi Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared…
Full Summary
Atai Beckley N.V. stock logo
ATAI
Atai Beckley
$7.35
COMP360 Treatment-resistant depression
NDA
11/9/2026 - NDA submission Compass Pathways plc announced the Company completed its submission of a New Drug Application (NDA)…
Full Summary
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$30.23
+0.6%
+45.3%
The price history of VRDN in the last 30 days
VRDN-008 treatment of rare and autoimmune diseases
Phase 1
11/9/2026 - Positive Results Viridian Therapeutics, Inc y announced positive phase 1 results for VRDN-008.
Full Summary
Spruce Biosciences, Inc. stock logo
SPRB
Spruce Biosciences
$40.54
+0.1%
+0.3%
The price history of SPRB in the last 30 days
CRHX-101 for Congenital Adrenal Hyperplasia ("CAH") 11/9/2026 - Provided Update Spruce Biosciences, Inc. announced that it has separated the company's CRHX-101 (formerly SPR-202)…
Full Summary
Hemab Therapeutics Holdings, Inc. stock logo
COAG
Hemab Therapeutics
$39.79
+1.9%
+24.0%
The price history of COAG in the last 30 days
HMB-001 in Glanzmann Thrombasthenia
Phase 3
11/9/2026 - Initiation Hemab Therapeutics announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig…
Full Summary
Veradermics, Incorporated stock logo
MANE
Veradermics
$124.32
-1.0%
+1.9%
The price history of MANE in the last 30 days
VDPHL01 Patient Experiences With Pattern Hair Loss
Phase 2/3
11/9/2026 - Top-line results Veradermics, Incorporated announced positive topline results from Part B of its randomized, double-…
Full Summary
BlossomHill Therapeutics, Inc. stock logo
BLSM
BlossomHill Therapeutics
$14.66
-3.1%
+3.5%
The price history of BLSM in the last 30 days
BH-30643 Treatment of Advanced EGFR C797S-positive NSCLC 11/9/2026 - Outcome BlossomHill Therapeutics, Inc. announced the outcome of its End-of-Phase 1 meeting with the U.S. F…
Full Summary
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
$1.84
+24.0%
-19.9%
The price history of ADAG in the last 30 days
muzastotug Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response 11/9/2026 - Enrollment Update Adagene Inc. announced completion of enrollment in its randomized Phase 2 dose-optimization trial …
Full Summary
Monte Rosa Therapeutics, Inc. stock logo
GLUE
Monte Rosa Therapeutics
$9.28
+2.3%
-13.0%
The price history of GLUE in the last 30 days
MRT-8102 For the treatment of inflammatory diseases 11/9/2026 - Presentation Monte Rosa Therapeutics, Inc. announced the presentation of preclinical data showing that MRT-8102,…
Full Summary
Nkarta, Inc. stock logo
NKTX
Nkarta
$1.19
-5.2%
-32.3%
The price history of NKTX in the last 30 days
NKX019 Relapsed/refractory B cell malignancies 11/9/2026 - Initial Data Nkarta announced positive initial clinical data from its Ntrust clinical trial program evaluating N…
Full Summary
NovoCure Limited stock logo
NVCR
NovoCure
$10.83
-2.8%
-27.3%
The price history of NVCR in the last 30 days
Optune Lua For the Treatment of Metastatic Non-Small Cell Lung Cancer 11/9/2026 - Provided Update Novocure announced today that it has received a Not Approvable Letter from the U.S. Food and Drug A…
Full Summary
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$51.55
-0.2%
-17.7%
The price history of CYTK in the last 30 days
Aficamten Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) 11/9/2026 - New Data Cytokinetics, announced that new data related to aficamten were presented at the Hypertrophic Cardi…
Full Summary
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$70.85
-0.3%
-0.9%
The price history of MNPR in the last 30 days
ALXN1840 (tiomolibdate choline, TMC) Wilson Disease
Phase 3
11/9/2026 - Presentation Monopar Therapeutics Inc. announced the presentation of baseline data from the Phase 3 FoCus trial…
Full Summary
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$0.73
-2.2%
-44.0%
The price history of ALLO in the last 30 days
ALLO-329 For the Treatment of Autoimmune Diseases 11/9/2026 - Efficacy and Safety Data Allogene Therapeutics, Inc. announced preliminary safety, efficacy and translational data from the…
Full Summary
BioVie Inc. stock logo
BIVI
BioVie
$0.98
-1.5%
-28.5%
The price history of BIVI in the last 30 days
Bezisterim For Parkinson's Disease Patients 11/9/2026 - Findings Update BioVie Inc. announced new biomarker findings from the ADDRESS-LC trial of bezisterim were presented …
Full Summary
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10.40
-2.9%
-37.9%
The price history of JANX in the last 30 days
JANX011 in Patients with Autoimmune Disease
Phase 1
11/9/2026 - Results Janux Therapeutics, Inc announced initial clinical results from the Phase 1 study of JANX011 in he…
Full Summary
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.04
-1.4%
-0.5%
The price history of HOWL in the last 30 days
WTX-124 Solid Tumors 11/9/2026 - Clinical Data Werewolf Therapeutics, announced new clinical data from its Phase 1/1b clinical trial of WTX-124 a…
Full Summary
Polaryx Therapeutics, Inc. stock logo
PLYX
Polaryx Therapeutics
$1.65
+3.1%
-14.1%
The price history of PLYX in the last 30 days
PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis 11/9/2026 - Provided Update Polaryx Therapeutics, Inc announces the activation of the first clinical trial site for SOTERIA, its…
Full Summary
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
$0.65
-1.7%
-27.8%
The price history of PLRX in the last 30 days
PLN-101095 Inhibitor of αvβ8 and αvβ1 integrins in development for the treatment of solid tumors 11/9/2026 - Presentation Pliant Therapeutics, Inc. announced the presentation of preclinical proof-of-concept data and new c…
Full Summary
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$42.17
+5.0%
-15.7%
The price history of CRSP in the last 30 days
CTX310 Treatments for Cardiovascular Diseases 11/9/2026 - Data Presentation CRISPR Therapeutics today presented clinical data from its Phase 1b clinical trial evaluating CTX310…
Full Summary
Veradermics, Incorporated stock logo
MANE
Veradermics
$124.32
-1.0%
+1.9%
The price history of MANE in the last 30 days
VDPHL01 Patient Experiences With Pattern Hair Loss 11/8/2026 - Provided Update Veradermics, Incorporated announced it will host an investor call and live webcast on Monday, Novem…
Full Summary
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$42.17
+5.0%
-15.7%
The price history of CRSP in the last 30 days
CTX112 In relapsed or refractory (R/R) CD19-positive B-cell malignancies 11/8/2026 - Provided Update CRISPR Therapeutics today provided an update on zugocabtagene geleucel (zugo-cel; formerly CTX112™…
Full Summary
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.12
+9.3%
-24.7%
The price history of CABA in the last 30 days
rese-cel treatment for multiple autoimmune diseases Phase 1/2 11/8/2026 - Clinical Data Cabaletta Bio, Inc. announced new Phase 1/2 clinical data on resecabtagene autoleucel (rese-cel) to…
Full Summary
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$43.46
+1.1%
-24.1%
The price history of ARWR in the last 30 days
plozasiran In Patients with Familial Chylomicronemia Syndrome 11/7/2026 - Results Arrowhead Pharmaceuticals, Inc. today presented results on two of the RNA interference (RNAi) base…
Full Summary
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$276.08
-0.9%
+8.7%
The price history of JNJ in the last 30 days
Icotrokinra For adults and adolescents with plaque psoriasis
Phase 3
11/7/2026 - Positive Results Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotroki…
Full Summary
argenex SE stock logo
ARGX
argenex
$946.12
-0.1%
+14.6%
The price history of ARGX in the last 30 days
VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis
Phase 3
11/7/2026 - Data argenx SE announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained impro…
Full Summary
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$17.58
+5.2%
+16.6%
The price history of RARE in the last 30 days
UX111 For Sanfilippo syndrome type A (MPS IIIA) UK MHRA 11/6/2026 - Provided Update Ultragenyx announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted…
Full Summary
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,392.09
-1.7%
+12.0%
The price history of LLY in the last 30 days
tirzepatide For obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. 11/6/2026 - Provided Update Eli Lilly and Company and Hims & Hers Health, Inc. announced an agreement to help expand access to…
Full Summary
MSLE
Satellos Bioscience
$6.26
+0.9%
-2.9%
The price history of MSLE in the last 30 days
BASECAMP in boys ages 7, 8 or 9 with Duchenne muscular dystrophy (DMD). 11/6/2026 - Feedback Satellos Bioscience Inc announced that, following feedback from the U.S. Food and Drug Administratio…
Full Summary
InflaRx N.V. stock logo
IFRX
InflaRx
$1.10
-4.8%
-24.5%
The price history of IFRX in the last 30 days
Izicopan small molecule inhibitor of the C5a receptor (C5aR) 11/6/2026 - Peer-reviewed publication InflaRx N.V. announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izi…
Full Summary
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$45.06
+0.5%
-5.2%
The price history of PLSE in the last 30 days
nPulse™ Vybrance™ treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs) 11/6/2026 - Results Pulse Biosciences, Inc. announced interim six-month results from PRECISE-BTN, a prospective, multic…
Full Summary
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$271.48
+0.1%
+18.1%
The price history of ASND in the last 30 days
TransCon CNP In Children with Achondroplasia 11/6/2026 - Positive Opinion Ascendis Pharma A/S announced that the Committee for Orphan Medicinal Products (COMP) of the Europ…
Full Summary

Frequently Asked Questions

This calendar tracks PDUFA target dates, NDA/BLA submissions and reviews, regulatory meeting outcomes, early-phase trial results, and special designations such as RMAT, Breakthrough Therapy, or orphan status.

This column shows the current stage or outcome of the FDA-related event listed, such as PDUFA Target Date Set, CRL Issued, Approved, or Designation Granted. It gives you a quick snapshot of where the drug is in the regulatory process and what action has occurred (or is expected).

Phase 1: Focuses on safety and dosage in a small group of healthy volunteers.

Phase 2: Explores effectiveness and side effects in a larger patient group.

Phase 3: Confirms effectiveness, monitors side effects, and compares with standard treatments in large populations. This is usually the last step before FDA submission.

Special FDA designations are programs designed to expedite the development and review of promising therapies. Breakthrough Therapy designation is granted to drugs that may offer substantial improvement over existing treatments for serious conditions. Orphan Drug designation is awarded to treatments targeting rare diseases affecting fewer than 200,000 people in the U.S. Other fast-track designations include RMAT (Regenerative Medicine Advanced Therapy), Fast Track, and Accelerated Approval.

Yes, you can export the data to Excel for further sorting, filtering, or integration into personal analytics tools.

  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process